EP1572724A4 - Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy - Google Patents

Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy

Info

Publication number
EP1572724A4
EP1572724A4 EP03711418A EP03711418A EP1572724A4 EP 1572724 A4 EP1572724 A4 EP 1572724A4 EP 03711418 A EP03711418 A EP 03711418A EP 03711418 A EP03711418 A EP 03711418A EP 1572724 A4 EP1572724 A4 EP 1572724A4
Authority
EP
European Patent Office
Prior art keywords
kdr
vegf
diagnosis
therapy
binding peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03711418A
Other languages
German (de)
French (fr)
Other versions
EP1572724A2 (en
Inventor
Aaron K Sato
Daniel J Sexton
Robert C Ladner
Daniel T Dransfield
Rolf E Swenson
Edmund R Marinelli
Kondareddiar Ramalingam
Adrian D Nunn
Wronski Mathew A Von
Ajay Shrivastava
Sibylle Pochon
Philippe Bussat
Christophe Arbogast
Radhakrishna Pillai
Hong Fan
Karen E Linder
Bo Song
Palaniappa Nanjappan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bracco International BV
Dyax Corp
Original Assignee
Bracco International BV
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco International BV, Dyax Corp filed Critical Bracco International BV
Priority to EP10185498.2A priority Critical patent/EP2301587B1/en
Priority to EP08008365A priority patent/EP2014310B8/en
Publication of EP1572724A2 publication Critical patent/EP1572724A2/en
Publication of EP1572724A4 publication Critical patent/EP1572724A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Acoustics & Sound (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
EP03711418A 2002-03-01 2003-03-03 Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy Withdrawn EP1572724A4 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP10185498.2A EP2301587B1 (en) 2002-03-01 2003-03-03 KDR and VEGF/KDR binding peptides and their use in diagnosis
EP08008365A EP2014310B8 (en) 2002-03-01 2003-03-03 KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36085102P 2002-03-01 2002-03-01
US360851P 2002-03-01
US44041103P 2003-01-15 2003-01-15
US440411P 2003-01-15
PCT/US2003/006731 WO2003074005A2 (en) 2002-03-01 2003-03-03 Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP10185498.2A Division EP2301587B1 (en) 2002-03-01 2003-03-03 KDR and VEGF/KDR binding peptides and their use in diagnosis
EP08008365A Division EP2014310B8 (en) 2002-03-01 2003-03-03 KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

Publications (2)

Publication Number Publication Date
EP1572724A2 EP1572724A2 (en) 2005-09-14
EP1572724A4 true EP1572724A4 (en) 2007-03-14

Family

ID=27791656

Family Applications (3)

Application Number Title Priority Date Filing Date
EP10185498.2A Expired - Lifetime EP2301587B1 (en) 2002-03-01 2003-03-03 KDR and VEGF/KDR binding peptides and their use in diagnosis
EP08008365A Expired - Lifetime EP2014310B8 (en) 2002-03-01 2003-03-03 KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
EP03711418A Withdrawn EP1572724A4 (en) 2002-03-01 2003-03-03 Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP10185498.2A Expired - Lifetime EP2301587B1 (en) 2002-03-01 2003-03-03 KDR and VEGF/KDR binding peptides and their use in diagnosis
EP08008365A Expired - Lifetime EP2014310B8 (en) 2002-03-01 2003-03-03 KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

Country Status (7)

Country Link
EP (3) EP2301587B1 (en)
JP (2) JP2006514915A (en)
AU (2) AU2003213730A1 (en)
CA (2) CA2477836A1 (en)
ES (2) ES2398393T3 (en)
SI (1) SI2301587T1 (en)
WO (1) WO2003074005A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4336771B2 (en) 2001-03-09 2009-09-30 モルフォシス アーゲー Serum albumin binding moiety
US7666979B2 (en) * 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
CA2477935C (en) * 2002-03-01 2015-01-06 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
NO20026286D0 (en) * 2002-12-30 2002-12-30 Amersham Health As New peptides
KR101076053B1 (en) 2003-02-04 2011-10-21 브라코 인터내셔날 비.브이. Ultrasound contrast agents and process for the preparation thereof
EP2662087A1 (en) * 2003-04-22 2013-11-13 Ipsen Pharma Somatostatin vectors
AU2004308756B2 (en) 2003-12-22 2010-06-24 Bracco Suisse S.A. Gas-filled microvesicle assembly for contrast imaging
CN1960707B (en) 2004-06-03 2012-11-14 博莱科瑞士股份有限公司 Liposomal assembly for therapeutic and/or diagnostic use
JP4837663B2 (en) 2004-08-18 2011-12-14 ブラッコ・シュイス・ソシエテ・アノニム Gas-filled microvesicle composition for contrast imaging
EP1846015A4 (en) * 2005-01-19 2009-08-12 Mathew Mark Zuckerman Method, compositions and classification for tumor diagnostics and treatment
EP1714642A1 (en) 2005-04-18 2006-10-25 Bracco Research S.A. Pharmaceutical composition comprising gas-filled microcapsules for ultrasound mediated delivery
CN103204911B (en) * 2005-12-09 2015-04-01 布拉科瑞士有限公司 Targeting Vector-phospholipid Conjugates
EP2061517B1 (en) 2006-09-05 2010-06-02 Bracco Research S.A. Gas-filled microvesicles with polymer-modified lipids
WO2008075192A2 (en) * 2006-12-19 2008-06-26 Bracco International Bv Targeting and therapeutic compounds and gas-filled microvesicles comprising said com ounds
CA2748995C (en) 2008-10-07 2018-01-16 Bracco Suisse Sa Targeting construct comprising anti-polymer antibody and liposomes or microvesicles binding to the same
WO2011046991A2 (en) * 2009-10-15 2011-04-21 Gilead Connecticut, Inc. Certain substituted ureas as modulators of kinase activity
WO2014096165A2 (en) 2012-12-21 2014-06-26 Bracco Suisse Sa Gas-filled microvesicles
BE1021191B1 (en) 2014-08-29 2015-10-27 Anmi S.A. KIT FOR RADIOMARKING.
US11027030B2 (en) 2014-08-29 2021-06-08 Anmi S.A. Kit for radiolabelling
JP6803839B2 (en) 2014-12-18 2020-12-23 ブラッコ・スイス・ソシエテ・アノニムＢｒａｃｃｏ Ｓｕｉｓｓｅ ＳＡ Formulation of targeted gas-filled microvesicles
EP3308779B1 (en) * 2015-06-10 2019-08-07 Teikyo University Theranostic bubble preparation (tb), and method for using same
TR201723077A2 (en) * 2017-12-29 2019-07-22 Ege Ueniversitesi ULTRACE SENSITIVE MAGNETIC TARGET NANO DRUG CARRIER SYSTEM
US20200360289A1 (en) 2019-05-15 2020-11-19 Bracco Suisse Sa Freeze-dried product and gas-filled microvesicles suspension
US11717570B2 (en) 2019-05-15 2023-08-08 Bracco Suisse Sa Gas-filled microvesicles
CA3187052A1 (en) 2020-07-29 2022-02-03 Eddy Sotelo Perez Functionalized isonitriles and products, preparation and uses thereof
CN113740539B (en) * 2021-08-11 2023-07-25 中元汇吉生物技术股份有限公司 Kit for determining specific growth factors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000063380A1 (en) * 1999-04-16 2000-10-26 Genentech, Inc. Vascular endothelial cell growth factor variants and uses thereof
WO2001052875A1 (en) * 2000-01-18 2001-07-26 Ludwig Institute For Cancer Research Vegf-d/vegf-c/vegf peptidomimetic inhibitor
WO2002016412A2 (en) * 2000-08-18 2002-02-28 Dyax Corp. Binding polypeptides for b lymphocyte stimulator protein (blys)

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4131648A (en) 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4180646A (en) 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4391797A (en) 1977-01-05 1983-07-05 The Children's Hospital Medical Center Systems for the controlled release of macromolecules
US4718433A (en) 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
DE3834705A1 (en) 1988-10-07 1990-04-12 Schering Ag ULTRASONIC CONTRASTING AGENTS FROM GAS BUBBLES AND MICROPARTICLES CONTAINING FATTY ACID
DE3313947A1 (en) 1983-04-15 1984-10-18 Schering AG, 1000 Berlin und 4709 Bergkamen MICROPARTICLES AND GAS BUBBLES CONTAINING ULTRASONIC CONTRASTING AGENTS
DE3313946A1 (en) 1983-04-15 1984-10-18 Schering AG, 1000 Berlin und 4709 Bergkamen MICROPARTICLES AND GAS BUBBLES CONTAINING ULTRASONIC CONTRASTING AGENTS
US4900540A (en) 1983-06-20 1990-02-13 Trustees Of The University Of Massachusetts Lipisomes containing gas for ultrasound detection
US4899755A (en) 1985-05-08 1990-02-13 The General Hospital Corporation Hepatobiliary NMR contrast agents
MX174467B (en) 1986-01-23 1994-05-17 Squibb & Sons Inc 1,4,7-TRISCARBOXIMETHYL-1,4,7,10-TETRAAZACICLODO DECAN SUBSTITUTE IN 1 AND ANALOG COMPOUNDS
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
DE3726264A1 (en) 1987-08-07 1989-02-16 Bayer Ag METHOD FOR THE PRODUCTION OF MOISTURE-HARDENING BINDER COMPOUNDS AND THEIR USE
US4844882A (en) 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
IE61591B1 (en) 1987-12-29 1994-11-16 Molecular Biosystems Inc Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5118797A (en) 1989-08-28 1992-06-02 E. R. Squibb & Sons, Inc. Rhenium tris dioxime complexes
CA2065290C (en) 1989-08-28 2000-12-12 Randall B. Lauffer Hydroxy-aryl metal chelates for diagnostic nmr imaging
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5230882A (en) 1989-12-22 1993-07-27 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5123414A (en) 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
CA2034042C (en) 1990-01-18 1999-08-17 Adrian D. Nunn Boronic acid adducts of rhenium dioxime and technetium-99m dioxime complexes containing a biochemically active group
US5578292A (en) 1991-11-20 1996-11-26 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US5556610A (en) 1992-01-24 1996-09-17 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method
US5445813A (en) 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
IN172208B (en) 1990-04-02 1993-05-01 Sint Sa
US5183653A (en) 1990-04-13 1993-02-02 E. R. Squibb & Sons, Inc. Boronic acid adducts of metal dioxime complexes useful in labelling proteins and other amine-containing compounds
US5137928A (en) 1990-04-26 1992-08-11 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
AU636481B2 (en) 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
US5849261A (en) 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
ES2141102T3 (en) 1991-02-08 2000-03-16 Diatide Inc POLYPEPTIDES MARKED WITH TECNETIO-99M FOR THE GENERATION OF IMAGES.
GB9106686D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
GB9106673D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
ES2103947T5 (en) 1991-06-03 2001-05-16 Nycomed Imaging As IMPROVEMENTS INTRODUCED IN OR RELATED TO CONTRAST AGENTS.
IE80926B1 (en) 1991-07-05 1999-06-30 Nycomed Imaging As Improvements in or relating to contrast agents
US5808091A (en) 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
GB9200387D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200391D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200388D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
IL104084A (en) 1992-01-24 1996-09-12 Bracco Int Bv Long-lasting aqueous suspensions of pressure-resistant gas-filled microvesicles their preparation and contrast agents consisting of them
US5608110A (en) 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
HUT74827A (en) 1993-07-02 1997-02-28 Molecular Biosystems Inc Protein encapsulated insoluble gas microspheres and their preparation and use as ultrasonic imaging agents
WO1995003280A1 (en) 1993-07-19 1995-02-02 Resolution Pharmaceuticals Inc. Hydrazino-type radionuclide chelators having an n3s configuration
US5798091A (en) 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
US5574140A (en) 1993-09-03 1996-11-12 Resolution Pharmaceutical Inc. Hydrazino-type N2 S2 chelators
RU2138293C1 (en) 1993-12-15 1999-09-27 Бракко Рисерч С.А. Contrast substances for ultrasonic echography, contrast means containing these substances, and method of preparation thereof
GB9402867D0 (en) 1994-02-15 1994-04-06 Nycomed Imaging As Improvements in or relating to contrast agents
JP2891647B2 (en) 1994-03-11 1999-05-17 株式会社日本触媒 Organic sulfide compound and method for producing the same
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US5582814A (en) 1994-04-15 1996-12-10 Metasyn, Inc. 1-(p-n-butylbenzyl) DTPA for magnetic resonance imaging
CN1148813A (en) 1994-04-20 1997-04-30 耐克麦德瑟鲁塔公司 Contrast medium
US5650135A (en) 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5662885A (en) 1994-07-22 1997-09-02 Resolution Pharmaceuticals Inc. Peptide derived radionuclide chelators
GB9417941D0 (en) 1994-09-06 1994-10-26 Nycomed Imaging As Improvements in or relating to contrast agents
US5556939A (en) 1994-10-13 1996-09-17 Merck Frosst Canada, Inc. TC or RE radionuclide labelled chelate, hexapeptide complexes useful for diagnostic or therapeutic applications
US6333021B1 (en) 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
DE4445065A1 (en) 1994-12-07 1996-06-13 Diagnostikforschung Inst Methods for in-vivo diagnostics using NIR radiation
IL116328A (en) 1994-12-16 1999-09-22 Bracco Research Sa Frozen suspension of gas microbubbles in frozen aqueous carrier for use as contrast agent in ultrasonic imaging
TW319763B (en) 1995-02-01 1997-11-11 Epix Medical Inc
GB9502065D0 (en) 1995-02-02 1995-03-22 Nycomed Imaging As Contrast media
US5837680A (en) 1996-02-16 1998-11-17 Children's Medical Center Corporation Pharmaceutical compositions comprising troponin subunits, fragments and analogs thereof and methods of their use to inhibit angiogenesis
KR100500334B1 (en) 1996-02-19 2005-09-09 아머샴 헬스 에이에스 Improvements in or Relating to Contrast Agents
BR9708470A (en) 1996-04-01 1999-04-13 Epix Medical Inc Bioactivated contrast agents for imaging for diagnostics
CZ28999A3 (en) 1996-08-02 1999-07-14 Nycomed Imaging As Use of contrast preparation
NZ335265A (en) 1996-10-21 2000-07-28 Nycomed Imaging As Gas containing contrast agents that may be co-administered with vasodilator drugs to enhance differences in return signal intensity from normal and hypoperfused myocardial tissue contrast agents
EP0963209A2 (en) 1996-10-28 1999-12-15 Marsden, John Christopher Improvements in or relating to diagnostic/therapeutic agents
EP0946202B1 (en) 1996-10-28 2003-09-10 Amersham Health AS Contrast agents
WO1998018501A2 (en) 1996-10-28 1998-05-07 Marsden, John, Christopher Improvements in or relating to diagnostic/therapeutic agents
ES2257771T3 (en) 1996-10-28 2006-08-01 Amersham Health As CONTRAST AGENTS.
WO1998018495A2 (en) 1996-10-28 1998-05-07 Marsden, John, Christopher Improvements in or relating to diagnostic/therapeutic agents
US5919967A (en) 1997-04-11 1999-07-06 Epix Medical, Inc. Process for synthesizing phosphodiesters
DE19717904A1 (en) 1997-04-23 1998-10-29 Diagnostikforschung Inst Acid-labile and enzymatically cleavable dye constructs for diagnostics with near infrared light and for therapy
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
US6245318B1 (en) 1997-05-27 2001-06-12 Mallinckrodt Inc. Selectively binding ultrasound contrast agents
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion Transdermal delivery system
GB9712525D0 (en) 1997-06-16 1997-08-20 Nycomed Imaging As Method
HUP0101245A3 (en) 1997-10-02 2003-10-28 Epix Pharmaceuticals Inc Cambr Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
US6165458A (en) 1997-12-26 2000-12-26 Pharmaderm Laboratories Ltd. Composition and method for dermal and transdermal administration of a cytokine
EP1056473B8 (en) 1998-02-09 2005-07-20 Bracco International B.V. Targeted delivery of biologically active media
BR9909420A (en) * 1998-03-31 2001-09-25 Du Pont Pharm Co Compound, kit, diagnostic or therapeutic metallopharmaceutical composition, ultrasound contrast agent composition, therapeutic radiopharmaceutical composition and diagnostic radiopharmaceutical composition
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US6312665B1 (en) 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
CN1345334A (en) * 1999-01-29 2002-04-17 伊姆克罗尼系统公司 Antibodies specific to KDR and uses thereof
US6294525B1 (en) 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
EP2279757A3 (en) 2000-06-02 2011-08-03 Bracco Suisse SA Compounds for targeting endothelial cells
CA2413328A1 (en) * 2000-06-21 2001-12-27 Milind Rajopadhye Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000063380A1 (en) * 1999-04-16 2000-10-26 Genentech, Inc. Vascular endothelial cell growth factor variants and uses thereof
WO2001052875A1 (en) * 2000-01-18 2001-07-26 Ludwig Institute For Cancer Research Vegf-d/vegf-c/vegf peptidomimetic inhibitor
WO2002016412A2 (en) * 2000-08-18 2002-02-28 Dyax Corp. Binding polypeptides for b lymphocyte stimulator protein (blys)

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BINETRUY-TOURNAIRE ROSELYNE ET AL: "Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 19, no. 7, 3 April 2000 (2000-04-03), pages 1525 - 1533, XP002179245, ISSN: 0261-4189 *
FAIRBROTHER W J ET AL: "NOVEL PEPTIDES SELECTED TO BIND VASCULAR ENDOTHELIAL GROWTH FACTOR TARGET THE RECEPTOR-BINDING SITE", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 37, no. 51, 22 December 1998 (1998-12-22), pages 17754 - 17764, XP000876734, ISSN: 0006-2960 *
HAIYAN JIA ET AL: "PEPTIDES ENCODED BY EXON 6 OF VEGF INHIBIT ENDOTHELIAL CELL BIOLOGICAL RESPONSES AND ANGIOGENESIS INDUCED BY VEGF", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 283, no. 1, 2001, pages 164 - 173, XP002941058, ISSN: 0006-291X *
IWAMOTO Y ET AL: "YIGSR, A SYNTHETIC LAMININ PENTAPEPTIDE, INHIBITS EXPERIMENTAL METASTATIS FORMATION", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 238, no. 4830, 20 November 1987 (1987-11-20), pages 1132 - 1134, XP001135169, ISSN: 0036-8075 *
LECOUTER JENNIFER ET AL: "Identification of an angiogenic mitogen selective for endocrine gland endothelium", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 412, no. 6850, 30 August 2001 (2001-08-30), pages 877 - 884, XP002194811, ISSN: 0028-0836 *
SATO A K ET AL: "Development of mammalian serum albumin affinity purification media by peptide phage display", BIOTECHNOLOGY PROGRESS, XX, XX, vol. 18, no. 2, January 2002 (2002-01-01), pages 182 - 192, XP002348553, ISSN: 8756-7938 *
SHRIVASTAVA A ET AL: "A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases.", PROTEIN ENGINEERING, DESIGN & SELECTION : PEDS. SEP 2005, vol. 18, no. 9, September 2005 (2005-09-01), pages 417 - 424, XP002375785, ISSN: 1741-0126 *

Also Published As

Publication number Publication date
EP1572724A2 (en) 2005-09-14
SI2301587T1 (en) 2014-11-28
ES2506142T3 (en) 2014-10-13
AU2003213730A1 (en) 2003-09-16
EP2301587A3 (en) 2011-04-06
JP2006514915A (en) 2006-05-18
EP2014310A3 (en) 2009-09-09
CA2477836A1 (en) 2003-09-12
AU2009201114B2 (en) 2012-01-19
EP2301587B1 (en) 2014-06-25
CA2666005C (en) 2016-01-19
EP2014310B1 (en) 2012-10-24
CA2666005A1 (en) 2003-09-12
JP5039075B2 (en) 2012-10-03
WO2003074005A8 (en) 2005-07-21
EP2014310A2 (en) 2009-01-14
EP2014310B8 (en) 2012-12-26
WO2003074005A2 (en) 2003-09-12
JP2009161549A (en) 2009-07-23
EP2301587A2 (en) 2011-03-30
ES2398393T3 (en) 2013-03-15
AU2009201114A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
AU2003278807A8 (en) KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
EP1572724A4 (en) Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
IL172316A0 (en) Novel compounds and their use in therapy
IL172826A0 (en) Quinoline derivates and their use in therapy
HK1081448A1 (en) Bispecific anti-erb-b antibodies and their use in tumor therapy
ZA200703699B (en) Nitrobenzindoles and their use in cancer therapy
EP1825005A4 (en) Mer diagnostic and therapeutic agents
EP1781685A4 (en) Therapeutic and diagnostic agents
IL203007A0 (en) Nogo-a binding with enhanced affinity and pharmaceutical use thereof
EP1838288A4 (en) Therapeutic materials and methods
ZA200606225B (en) Modified human four helical bundle polypeptides and their uses
GB0308382D0 (en) Therapeutic methods and means
SI1639013T1 (en) Pan-kir2dl NK-receptor antibodies and their use in diagnostic and therapy
SI1660532T1 (en) Fusion polypeptides, and use thereof in antivascular tumor therapy
HK1209049A1 (en) Survivin-derived peptides and use thereof
AU2003209459A8 (en) Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
GB0402129D0 (en) Therapeutic and diagnostic peptides
GB0321694D0 (en) Genes and their therapeutic use
EP1838728A4 (en) Human protooncogene and protein encoded therein
HK1082746A1 (en) Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
GB0424871D0 (en) Antibodies and their use in therapy
GB0404199D0 (en) Therapeutic and diagnostic peptides 2
GB0225688D0 (en) Therapeutic compounds and their use in therapy
IL173796A0 (en) Polynucleotides, polypeptides and antibodies and use thereof in treating tsg101-associated diseases
GB0203043D0 (en) Benzimidazloe compounds their preparation and their use in therapy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041001

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

A4 Supplementary search report drawn up and despatched

Effective date: 20060421

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20070214

17Q First examination report despatched

Effective date: 20071016

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090505